Uptake of prenatal diagnostic testing for retinoblastoma compared to other hereditary cancer syndromes in the Netherlands
Tóm tắt
Since the 1980s the genetic cause of many hereditary tumor syndromes has been elucidated. As a consequence, carriers of a deleterious mutation in these genes may opt for prenatal diagnoses (PND). We studied the uptake of prenatal diagnosis for five hereditary cancer syndromes in the Netherlands. Uptake for retinoblastoma (Rb) was compared with uptake for Von Hippel–Lindau disease (VHL), Li–Fraumeni syndrome (LFS), familial adenomatous polyposis (FAP), and hereditary breast ovarian cancer (HBOC). A questionnaire was completed by all nine DNA-diagnostic laboratories assessing the number of independent mutation-positive families identified from the start of diagnostic testing until May 2013, and the number of PNDs performed for these syndromes within these families. Of 187 families with a known Rb-gene mutation, 22 had performed PND (11.8%), this was significantly higher than uptake for FAP (1.6%) and HBOC (<0.2%). For VHL (6.5%) and LFS (4.9%) the difference was not statistically significant. PND for Rb started 3 years after introduction of diagnostic DNA testing and remained stable over the years. For the other cancer syndromes PND started 10–15 years after the introduction and uptake for PND showed an increase after 2009. We conclude that uptake of PND for Rb was significantly higher than for FAP and HBOC, but not different from VHL and LFS. Early onset, high penetrance, lack of preventive surgery and perceived burden of disease may explain these differences.
Tài liệu tham khảo
Offit K, Kohut K, Clagett B et al (2006) Cancer genetic testing and assisted reproduction. J Clin Oncol 24:4775–4782
Lammens C, Bleiker E, Aaronson N et al (2009) Attitude towards pre-implantation genetic diagnosis for hereditary cancer. Fam Cancer 8:457–464
Dommering CJ, van den Heuvel MR, Moll AC et al (2010) Reproductive decision-making: a qualitative study among couples at increased risk of having a child with retinoblastoma. Clin Genet 78:334–341
Dommering CJ, Garvelink MM, Moll AC et al (2012) Reproductive behavior of individuals with increased risk of having a child with retinoblastoma. Clin Genet 81:216–223
Rich TA, Liu M, Etzel CJ et al (2014) Comparison of attitudes regarding preimplantation genetic diagnosis among patients with hereditary cancer syndromes. Fam Cancer 13:291–299
Mitchell C, Nicolaides K, Kingston J et al (1988) Prenatal exclusion of hereditary retinoblastoma. Lancet 1:826
Ao A, Wells D, Handyside AH et al (1998) Preimplantation genetic diagnosis of inherited cancer: familial adenomatous polyposis coli. J Assist Reprod Genet 15:140–144
Harper JC, Geraedts J, Borry P et al (2013) Current issues in medically assisted reproduction and genetics in Europe: research, clinical practice, ethics, legal issues and policy. European Society of Human Genetics and European Society of Human Reproduction and Embryology. Eur J Hum Genet 21(Suppl 2):S1–21
Council of Europe. Background document on preimplantation and prenatal genetic testing. http://www.coe.int/t/dg3/healthbioethic/Activities/07_Human_genetics_en/default_en.asp. Updated 7-5-2015. Accessed 28-3-2016
Quinn GP, Vadaparampil ST, Bower B et al (2009) Decisions and ethical issues among BRCA carriers and the use of preimplantation genetic diagnosis. Minerva Med 100:371–383
Wang CW, Hui EC (2009) Ethical, legal and social implications of prenatal and preimplantation genetic testing for cancer susceptibility. Reprod Biomed Online 19(Suppl 2):23–33
Niermeijer MF, de Wert G, Dondorp W (2006) Preimplantation genetic diagnosis for cancer. Lancet Oncol 7:794–795
Niermeijer MF, de Die-Smulders CE, Page-Christiaens GC, de Wert GM (2008) Genetic cancer syndromes and reproductive choice: dialogue between parents and politicians on preimplantation genetic diagnosis. Ned Tijdschr Geneeskd 152:1503–1506
Clancy T (2010) A clinical perspective on ethical arguments around prenatal diagnosis and preimplantation genetic diagnosis for later onset inherited cancer predispositions. Fam Cancer 9:9–14
Leading edge (2006) Ethics of preimplantation genetic diagnosis for cancer. Lancet Oncol 7:611
van Oostrom I, Meijers-Heijboer H, Lodder LN et al (2003) Long-term psychological impact of carrying a BRCA1/2 mutation and prophylactic surgery: a 5-year follow-up study. J Clin Oncol 21:3867–3874
Ethics Committee of American Society for Reproductive Medicine (2013) Use of preimplantation genetic diagnosis for serious adult onset conditions: a committee opinion. Fertil Steril 100:54–57
Cobben JM, Brocker-Vriends AH, Leschot NJ (2002) Prenatal diagnosis for hereditary predisposition to mammary and ovarian carcinoma—defining a position. Ned Tijdschr Geneeskd 146:1461–1465
Lodder LN, Frets PG, Trijsburg RW et al (2000) Attitudes towards termination of pregnancy in subjects who underwent presymptomatic testing for the BRCA1/BRCA2 gene mutation in The Netherlands. J Med Genet 37:883–884
Lohmann DR, Gallie BL (2015) Retinoblastoma. http://www.ncbi.nlm.nih.gov/books/NBK1452/. Updated 19-11-2015. Accessed 22-4-2016
Frantzen C, Links TP, Giles RH (2015) Von Hippel–Lindau Disease. http://www.ncbi.nlm.nih.gov/books/NBK1463/. Updated 6-8-2015. Accessed 14-3-2016
Schneider K, Zelley K, Nichols KE, Garber J (2013) Li–Fraumeni syndrome. http://www.ncbi.nlm.nih.gov/books/NBK1311/. Updated 11-4-2013. Accessed 17-12-2015
Jasperson KW, Burt RW (2014) APC-associated polyposis conditions. http://www.ncbi.nlm.nih.gov/books/NBK1345/. Updated 27-3-2014. Accessed 17-4-2016
Petrucelli N, Daly MB, Feldman GL (2013) BRCA1 and BRCA2 hereditary breast and ovarian cancer. http://www.ncbi.nlm.nih.gov/books/NBK1247/. Updated 26-9-2013. Accessed 17-11-2015
Friend SH, Bernards R, Rogelj S et al (1986) A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 323:643–646
Latif F, Tory K, Gnarra J et al (1993) Identification of the von Hippel–Lindau disease tumor suppressor gene. Science 260:1317–1320
Malkin D, Li FP, Strong LC et al (1990) Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250:1233–1238
Kinzler KW, Nilbert MC, Su LK et al (1991) Identification of FAP locus genes from chromosome 5q21. Science 253:661–665
Miki Y, Swensen J, Shattuck-Eidens D et al (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66–71
Wooster R, Bignell G, Lancaster J et al (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378:789–792
Brandt AC, Tschirgi ML, Ready KJ et al (2010) Knowledge, attitudes, and clinical experience of physicians regarding preimplantation genetic diagnosis for hereditary cancer predisposition syndromes. Fam Cancer 9:479–487
Julian-Reynier C, Chabal F, Frebourg T et al (2009) Professionals assess the acceptability of preimplantation genetic diagnosis and prenatal diagnosis for managing inherited predisposition to cancer. J Clin Oncol 27:4475–4480
Gallie B (2009) Canadian guidelines for retinoblastoma care. Can J Ophthalmol 44:639–642
Sheldon T (2008) Netherlands debates screening for breast cancer. BMJ 336:1270